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Simple Summary: Standard treatment for chronic lymphocytic leukemia (CLL) has experienced a
dramatic change over the last years. Until recently, CLL was treated using chemotherapy in combi-
nation with anti-CD20 antibody-based immunotherapy. Depending on age and clinical condition,
patients received more or less intensive chemotherapy and were at risk of side effects commonly
associated with chemotherapy. Currently, patients are mostly treated with so-called novel agents,
including BTK inhibitors, Bcl-2 inhibitors and PI3K inhibitors, which are generally well tolerated
but have a specific side effect profile. CLL is a chronic disease; therefore, most patients will relapse
on or after treatment with these drugs and will require multiple lines of therapy. In this review,
we present the current treatment options for patients with CLL and discuss the optimal treatment
approaches and sequences, taking into account the specific side effects of each novel agent in the
context of different clinical settings.
Abstract: After impressive developments in recent years with the rise of new targeted agents,
chemoimmunotherapy (CIT) only plays a minor role in the treatment of patients with chronic
lymphocytic leukemia (CLL). Inhibitors of the Bruton tyrosine kinase (BTK), such as ibrutinib or
more recently acalabrutinib, are highly effective, even in poor-risk or chemo-refractory patients.
Venetoclax, an inhibitor of the anti-apoptotic BCL2 protein and, to a lesser extent, phosphoinositide-3
kinase (PI3K) delta inhibitors, add to the armamentarium of targeted agents for the treatment of
CLL. Furthermore, anti-CD20 monoclonal antibodies are used very successfully either alone or in
combination with BTK, BCL2 or PI3K inhibitors. Despite these advances, there is still an ongoing
pursuit for new therapeutic approaches in the treatment of CLL. An even bigger challenge poses the
determination of the optimal combination and sequence of those drugs. Here, we give an overview
of current treatment options in CLL, weighing the advantages and disadvantages of each approach
in the light of different clinical settings.
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1. Introduction
In the Western world, chronic lymphocytic leukemia (CLL) remains the most common
leukemia in adults [1,2], with an average age of approximately 70 years at the time of diag-
nosis [1,3]. Its incidence is 4.2/100,000 population per year and rises to over 30/100,000 in
people >80 years of age. Nevertheless, routine screening for CLL is not recommended at
any age [3]. Diagnostic criteria for CLL are assessed by blood smear and immunopheno-
typing, requiring the presence of ≥5 × 109/L monoclonal B lymphocytes in the peripheral
blood, sustained for at least 3 months with a specific immunophenotype co-expressing
CD5, CD19, and CD23 [4]. Clonal disease is determined by light chain restriction assessed
by flow cytometry. Malignant cells are morphologically mature lymphocytes with sparse
cytoplasm and condensed nuclei. Prolymphocytes with prominent nucleoli constitute
fewer than 55% of lymphoid cells [5]. CLL has a heterogenous clinical course which is
mostly indolent, but can be more aggressive with rapid progression in some cases [4].
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It is thought that underlying genetic alterations are mainly responsible for individual
disease courses, with the most relevant genetic aberrations being del(17p), TP53-mutation,
and unmutated IGHV status [6–10]. The CLL International Prognostic Index (CLL-IPI),
which combines genetic, biochemical, and clinical parameters, can be used as a prognostic
tool before the initiation of treatment [11]. It includes TP53-, IGHV-mutational status,
serum β2-microglobulin concentration, clinical stage, and age, and allows physicians to
take a more targeted approach to the management of patients with CLL. Although well
established in the setting of chemoimmunotherapy (CIT), its role in the era of front-line
treatment with targeted agents is yet to be determined [12]. Over the last few years, there
have been tremendous efforts to improve the treatment for patients with CLL, resulting in
the development of targeted therapies trying to replace classic cytostatic agents. Despite
these improvements, allogeneic stem cell therapy still remains the only curative treatment
option [13]. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab
(FCR) has been the standard of care for young, fit patients [14–16], even though it is limited
by its side effects and reduced activity in patients with genetic risk factors such as TP53
mutation, del(17p), del(11q), NOTCH1 mutation and unmutated IGHV status [8]. With the
introduction of the Bruton tyrosine kinase inhibitor (BTKi) ibrutinib, which irreversibly
inhibits Bruton tyrosine kinase (BTK), an essential enzyme in the B cell receptor (BCR)
signaling pathway, the era of targeted agents for CLL patients began [17–19]. Recently, acal-
abrutinib, a second-generation BTKi with higher selectivity for BTK than ibrutinib [20], was
approved by the U.S. Food and Drug Administration (FDA) and the European Medicines
Agency (EMA) for the treatment of CLL patients.
Shortly after the approval of ibrutinib, the combination of idelalisib ± rituximab, a
phosphoinositide 3-kinase (PI3K) delta inhibitor, found its way into the European Society
for Medical Oncology (ESMO) clinical practice guidelines for CLL in 2015 [21,22]. In 2018,
another PI3K inhibitor, duvelisib, was approved for relapsed/refractory (r/r) CLL by the
FDA [23]. Moreover, with the novel agent venetoclax, which inhibits anti-apoptotic BCL2,
leading to the apoptosis of CLL cells and is used in different clinical settings from first-line
to relapse settings [24–27], physicians now have a broad spectrum of treatment options.
Despite all these improvements, treatment is only initiated when patients develop active
disease according to the criteria of the International Workshop on Chronic Lymphocytic
Leukemia [4] (iwCLL), and a “watch and wait” approach is feasible in many cases.
The purpose of this review is to provide an overview of current treatment options in
CLL with high relevance in clinical practice.
2. Watch and Wait
When CLL is diagnosed at an early disease stage, as determined according to Rai
or Binet [28] (Binet A and B or Rai 0, I and II without active disease [29,30]), no therapy
or risk assessment is necessary and patients should be monitored every 3 months in the
first year and disease dynamic-adapted thereafter [3]. This “watch and wait” approach is
justified because early treatment with chemotherapy (chlorambucil or fludarabine) does
not result in prolonged overall survival [31,32]. Whether early treatment with the BTK
inhibitor ibrutinib results in prolonged overall survival (OS) is currently being investigated
by the German CLL Study Group in the CLL12 trial [33].
3. Chemoimmunotherapy
Even though novel agents such as BTKi and BCL2 inhibitors are the standard of
care in most therapeutic settings, chemoimmunotherapy (CIT) still has its place in the
treatment landscape of CLL. The combination of the chimeric CD20 antibody rituximab
with fludarabine and cyclophosphamide (FCR regime) has been the standard for young, fit
patients for more than a decade. Rituximab, which is used for most B cell malignancies,
activates the classical pathway of the complement system and triggers antibody-dependent
cell-mediated cytotoxicity (ADCC) [34]. The FCR regime was established by the CLL-8
trial, a phase 3 randomized, controlled trial, which included young, fit (CIRS score < 6
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and glomerular filtration rate > 70 mL/min) patients with CLL (BINET B or C) [15]. It
compared FCR and FC (fludarabine, cyclophosphamide), and showed an improvement
in PFS for FCR (56.8 months versus 32.9 months, hazard ratio (HR) 0.59; p < 0.001), while
the median overall survival (OS) was not reached in the FCR arm versus 86 months in
the FC arm. There are certain cytogenetic/molecular subgroups which benefit the most
from FCR, i.e., patients with immunoglobulin heavy chain variable region (IGHV) mutated
CLL whos median PFS has not been reached [16]. These data indicate that there might
be a proportion of young, fit patients with IGVH-mutated CLL that could potentially be
cured with FCR [35]. In contrast, patients with unmutated IGHV, mutated TP53, mutated
NOTCH1, del(17p), del(11q) showed inferior PFS. Therefore, it is crucial to identify the
subgroup of patients who might benefit from FCR treatment achieving long-term disease
control. The side effects of FCR, such as hematological toxicity and infectious complications,
are well documented [36,37], making it a feasible treatment choice only for young, fit
patients because dose reductions in FCR, which are an often used approach to minimize
the drug-related toxicity of FCR, result in reduced efficacy [38,39]. Although FCR is still a
reasonable treatment option for a small proportion of CLL patients, recent trials such as
the CLL-13 trial by the German CLL Study Group (GCLLSG) [40] or the FLAIR trial [41]
are challenging CIT and are probably shifting the standard of care to targeted agents even
more. In addition, FCR had a higher mortality than expected in recent phase 3 trials [42].
For elderly patients with CLL, the bendamustine–rituximab (BR) combination rather
than FCR is preferred if CIT is the treatment of choice. The subgroup analysis of patients
>65 years old in the CLL-10 trial of the GCLLSG (FCR vs. BR) showed a better toxicity
profile, with increased OS in this patient group for the BR regime (78.8% vs. 70.9%) [43,44].
Of interest, the MABLE trial indicated superior outcomes with BR in fludarabine-ineligible
patients with a lower bendamustine dose of 70mg/m2 [45,46]. Even though BR is effec-
tive, especially in elderly patients (>65 years) with untreated CLL, it showed inferiority
compared to ibrutinib in a direct comparison. The phase 3 Alliance trial by Woyach et al.
showed that ibrutinib was superior to treatment with BR with regard to PFS (74% vs. 87%),
but without a significant difference between the treatment groups regarding OS [47]. Of
note, grade ≥3 non-hematologic adverse events rates were lower with bendamustine plus
rituximab (63% vs. 74%), reflecting its still-valuable role in the treatment setting for elderly
patients; however, this could also be explained by a temporary versus a permanent therapy.
Taking into account that the median age at diagnosis of CLL is 65–70 years, which
makes the occurrence of comorbidities in these patients more likely, there is urgent need
for less toxic therapeutic options. For decades, chlorambucil (clb) has been the standard of
care for elderly, frail patients, even though, as a single agent, it only showed modest overall
response rates (ORR) of 37% with a median PFS of 14 months in previous trials [48]. To im-
prove the response rates, CD20-antibodies were added to chlorambucil as a chemotherapy
backbone. The addition of rituximab to chlorambucil led to an improved ORR (84%), with a
median PFS of 23.5 months in a phase 2 study [49]. The second CD20 monoclonal antibody
which was used as a combination partner for chlorambucil is obinutuzumab (GA101).
It is a glycoengineered type II CD20 and immunoglobulin G1 Fc-optimized monoclonal
antibody with a superior efficacy due to direct cytotoxicity and enhanced ADCC [50]. Even
as monotherapy, it showed a response rate of 62% in heavily pretreated patients [51].
The phase 3 CLL11 trial compared rituximab–chlorambucil with Obinutuzumab–
chlorambucil and chlorambucil monotherapy. The combination treatment arms showed
better ORR and PFS, with a median PFS of 11.1 (clb), 15.2 (rituximab–clb) and 26.7
(obinutuzumab–clb) months, respectively. In addition, obinutuzumab–clb was more fre-
quently associated with undetectable minimal residual disease (uMRD) [52], and obinu-
tuzumab led to a longer time to next therapy (TTNT) and improved OS, with the median
OS not reached for the obinutuzumab–clb group versus 73.1 months in the rituximab–clb
arm [53]. However, even though it was used as a comparison in clinical trials for elderly or
frail CLL patients over decades, newer, well-tolerated therapeutics such as BTKi or BCL2
inhibitors replaced clb as the standard of care in elderly or frail patients [27,54].
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4. BCL2 Inhibitors
Increased expression of the antiapoptotic protein B cell lymphoma 2 (BCL2) seems to
be responsible for rendering CLL cells resistant to apoptosis [55,56]. ABT-737 (navitoclax)
mimics BH3, a physiologic BCL2 antagonist, and was the first drug of this class to be
tested in clinical trials [57–59]. Initial results were promising, but further use of ABT-
737 was prevented by the occurrence of severe thrombocytopenia due to the concurrent
inhibition of BCL-xL, a protein required for platelet survival [60]. Venetoclax, formerly
known as ABT-199, is an orally administered inhibitor of BCL2 with higher selectivity
for BCL2 but less activity against BCL-xL, inducing the apoptosis of CLL cells in a TP53-
independent manner [24,61,62]. As a highly effective oral inhibitor of BCL2, venetoclax
was first approved in the r/r treatment setting for CLL patients with del(17p), based on the
two phase 2 trials M13-928 [25] and M14-032 [63]. Of note, for patients in the M13-982 trial
with del(17p), venetoclax showed an ORR of 77% and CR rate of 20% with a high uMRD
rate of 27% in peripheral blood, underlining its ability to induce deep remissions in this
high-risk CLL subgroup [25,64]. Over time, the initial issue of tumor lysis syndrome (TLS)
has been successfully mitigated by the implementation of a dose ramp-up schedule. In
detail, the venetoclax dose is raised from 20 mg to 50 mg to 100 mg to 200 mg to 400 mg
(target dose) daily in a step-by-step fashion every week [24].
Later on, the phase 3 MURANO trial showed improved PFS for the combination of
venetoclax and rituximab (VR) versus BR. In the MURANO trial, venetoclax was adminis-
tered for 24 cycles (400 mg daily) in combination with rituximab (six cycles every 4 weeks)
versus six cycles of CIT (BR) in patients with r/r CLL, including patients previously treated
with BTKi-based regimens. The combination of rituximab and venetoclax led to a signifi-
cant improvement of the 24 month PFS (84.9% vs. 36.3%) [26]. This advantage was seen
across all high-risk subgroups, including patients with del(17p) and unmutated IGHV
status. In addition, the high ORR (92%) resulted in an impressive uMRD rate of 84% in
the peripheral blood [26]. The sustained benefit of VR was shown in the 3-year follow-up
analysis, with PFS rates of 71.4% vs. 15.2% for BR and superior survival rates (OS 87.9%
vs. 79.5%) [65]. Most recently, with a median follow-up of 59.2 months, the VR group
demonstrated a median PFS of 53.6 months compared to 17 months for BR and 5-year OS
estimates of 82.1% vs. 62.2% for BR, respectively, confirming the initial results [66]. The PFS
estimate 36 months after the end of treatment (EOT) was 51.1% for patients who completed
2 years of venetoclax. Interestingly, for VR patients who reached EOT without disease
progression, uMRD at EOT (83/118) predicted improved OS (3-year post-EOT survival
estimate 95.3% versus 85% for those [35/118] with detectable MRD at EOT). In the context
of venetoclax therapy in r/r CLL patients, peripheral blood MRD assessment has been
shown to be a good surrogate for bone marrow MRD assessment, with reliable correlation
with long-term outcomes [67].
The approval of venetoclax as a second-line treatment for all CLL patients, regardless
of their del(17p) status, was made in June 2018 by the FDA, while the EMA approved
the combination of venetoclax and rituximab in October 2018. Both agencies based their
decision on the results of the MURANO trial [26].
Moving on, venetoclax recently found its way into the first-line treatment of CLL
patients due to the results of the CLL14 trial, a phase 3 trial which investigated the com-
bination of venetoclax and obinutuzumab in mostly elderly patients with comorbidities
vs. obinutuzumab–clb [27]. The combination of venetoclax and obinutuzumab led to an
improved 24-month PFS (88.2% vs. 64.1%), which was also observed in patients with
del(17p), TP53 mutation, or both, as well as in patients with non-mutated IGHV. The
recently presented 3-year follow-up showed a high ongoing rate of uMRD for the combina-
tion of venetoclax–obinutuzumab vs. obinutuzumab–clb (47.2% vs. 7.4%), emphasizing
the potential of venetoclax [68]. Of note, patients in the CLL14 trial were over 70 years old,
with a median age of 72 years, and had comorbidities with a median Cumulative Illness
Rating Scale score of 8 and a median creatinine clearance of 66.4 ml/minute. The efficacy of
venetoclax in younger, fit patients still needs to be proven. This question will probably be
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answered by the CLL13 trial (NCT02950051), which compares CIT (FCR or BR) vs. various
combinations of venetoclax (Ve), rituximab (R), obinutuzumab (G) and ibrutinib (I) (RVe vs.
GVe vs. GIVe) in treatment-naïve, fit CLL patients without del(17p) or TP53 mutation [40].
In summary, venetoclax induces high response rates and deep remissions, even in high-




Ibrutinib, which is an oral inhibitor of BTK, leads to an inhibition of CLL-cell migra-
tion, survival and, most importantly, proliferation [69,70], resulting in high ORR when
continuously administered. Ibrutinib binds covalently to cysteine 481, which is part of the
adenosine triphosphate (ATP)-binding pocket of BTK [71]. It was first approved for the
treatment of CLL patients by the FDA in 2014 in the relapsed/refractory setting, based on
a phase 1b/2 trial (PCYC-1102) where 85 patients with r/r CLL received a daily dose of
420 or 840 mg of ibrutinib [17]. In this trial, the ORR was 71%, independent of clinical or
genomic risk factors in both dose groups [18]. The recently published final analysis of the
RESONATE trial with a median follow-up of 65.3 months demonstrated a significantly
longer median PFS for r/r CLL patients treated with ibrutinib compared to ofatumumab
(44.1 versus 8.1 months, p < 0.001) [72]. These results were consistent in all high-risk
subgroups of patients (del(17p), TP53 mutation, unmutated IGHV status, del(11q)) who
comprised 82% of the entire study population. For high-risk relapsed CLL patients with
del(17p) and a median of two prior therapies, the phase 2 RESONATE-17 trial (PCYC-1117)
resulted in a PFS at 24 months of 63% [73].
Regarding treatment-naïve (tn) CLL patients, ibrutinib was compared to chlorambucil
in elderly patients (≥65 years) in the RESONATE-2 trial, with an improved ORR (ORR;
86% vs. 35%), 2-year PFS (89% vs. 34%), and 2-year OS (98% vs. 85%) [19]. The long-term
follow-up showed an estimated 5-year PFS and OS of 70% and 83% for ibrutinib compared
to 12% and 68% for chlorambucil, respectively. The investigator-assessed ORR was 92%,
with a CR rate of 30% [54]. The trial led to the approval for ibrutinib monotherapy in
patients with previously untreated CLL.
The efficacy of ibrutinib was further confirmed in two phase 3 trials. The Alliance trial
(A041202) evaluated the efficacy of ibrutinib either alone or in combination with rituximab
(ibrutinib ± rituximab, IR) compared to CIT (bendamustine plus rituximab, BR) in the
first-line treatment of older CLL patients (≥65 years) [47]. The other trial (E1912) evaluated
the efficacy of ibrutinib plus rituximab for six cycles (after an initial cycle of ibrutinib
monotherapy), followed by ibrutinib until disease progression, compared to six cycles
of CIT with fludarabine, cyclophosphamide, and rituximab (FCR) in patients 70 years of
age or younger [74]. Both studies showed an improved PFS for ibrutinib-treated patients.
However, the uMRD rate was significantly lower with ibrutinib-containing regimens in
both trials [47,74]. CIT with BR resulted in a uMRD rate of 8%, compared to 1% with
ibrutinib and 4% with IR, respectively [47]. In addition, the percentage of patients with
uMRD with FCR treatment was higher in the E1912 trial as well, as compared to IR
(59.2% vs. 8.3%) [74]. It is worth noting that in the E1912 trial, at a median follow-up of
33.6 months, the combination of ibrutinib plus rituximab showed an improved 3-year PFS
rate of 89.4% vs. 72.9% (HR 0.35; 95% CI 0.22–0.56; p < 0.001) compared to CIT in patients
with unmutated IGHV status. Nevertheless, in patients with IGHV-mutated CLL, there
was no significant difference regarding 3-year PFS (87.7% in the IR group vs. 88.0% in the
CIT group; HR 0.44; 95% CI 0.14–1.36) [74].
Although extended follow-up of the original RESONATE-2 study suggested that
remissions deepen over time with continued ibrutinib therapy, it is clear that continuous
and indefinite therapy with ibrutinib is required to maintain clinical benefit [75].
In elderly patients and comorbid patients, the iLLUMINATE trial tested the combina-
tion of ibrutinib and obinutuzumab against chlorambucil and obinutuzumab and showed a
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benefit in PFS for the combination of ibrutinib and obinutuzumab versus chlorambucil and
obinutuzumab [76], leading to the FDA and EMA approval of this combination. This phase
3 trial randomized 229 patients with tn CLL aged ≥65 years or younger than 65 years with
existing comorbidities to receive six cycles of obinutuzumab in combination with continu-
ous daily ibrutinib (until disease progression) or chlorambucil (0.5 mg/kg on days 1 and
15 every 28 days for six cycles). The median PFS in the ibrutinib and obinutuzumab group
had not been reached after a median follow-up of 31.3 months, compared to a median
PFS of 19 months in the chlorambucil and obinutuzumab group (p < 0.0001). The safety
analysis showed a higher AE rate in the ibrutinib and obinutuzumab group (58% serious
AEs vs. 35% in the chlorambucil and obinutuzumab group, respectively). The trial did not
include an ibrutinib monotherapy arm; therefore, the benefit of adding obinutuzumab to
ibrutinib remains unclear.
5.2. Acalabrutinib
Acalabrutinib was recently approved by the FDA for tn and r/r CLL. It is a second-
generation and more selective irreversible BTK inhibitor [20]. Compared to ibrutinib,
acalabrutinib shows equipotent BTK inhibition [77] but without the off-target effects on
other kinases [78,79], which probably explains some of the side effects of ibrutinib [80].
Acalabrutinib seems to have less inhibitory effect on healthy T cells compared to ibru-
tinib, probably due to its higher selectivity [80]. Acalabrutinib was first evaluated in a
phase 1/2 trial that included patients with relapsed CLL or small lymphocytic leukemia
(SLL) in need of treatment according to the IWCLL guidelines with at least one prior
CLL therapy [81]. Adequate organ function, exclusion of active infection, and an ECOG
performance score ≤ 2 was required. A total of 61 patients with a median age of 62 years
were included; 31% had deletion(17p) and 75% had an unmutated IGHV status. The ORR
was 95% with a well-tolerated safety profile, which appeared to be similar to that reported
with ibrutinib. Interestingly, in all patients with deletion(17p), a response to acalabrutinib
was documented.
Acalabrutinib was then tested in patients with treatment-naïve CLL in a phase 3,
multicenter trial (ELEVATE TN) [82]. In this trial, patients had a median age of 70 years,
and were randomized to receive acalabrutinib (Acb) with (n = 179) or without (n = 179)
obinutuzumab (G) or chlorambucil (Clb) with obinutuzumab (n = 177). It included patients
older than 65 years and younger than 65 years with concurrent comorbidities (Cumulative
Illness Rating Scale for Geriatrics score > 6 [83] or renal impairment with a creatinine clear-
ance of 30–69 mL/min). Patients with significant cardiovascular disease were excluded,
and concomitant treatment with warfarin or equivalent vitamin K antagonists was not
allowed. At median follow-up of 28.3 months (IQR 25.6–33.1), median PFS was longer with
G-Acb (not reached) and Acb monotherapy (not reached), compared to G-Clb (22.6 months,
20.2–27.6). Estimated PFS at 24 months was 93% with G-Acb (95% CI 87–96%) and 87%
with Acb monotherapy (95% CI 81–92%) versus 47% with G-Clb (95% CI 39–55%).
The recently published ASCEND study is a phase 3, multicenter trial which compared
acalabrutinib with treatment according to the investigator’s choice (idelalisib plus ritux-
imab or BR) in patients with r/r CLL. Patients had a median age of 67 years (32–90) and
had received a median of two therapies prior to study inclusion [84]. In this trial, 16% had
a del(17p) with a reported estimated 12-month PFS of 88% for acalabrutinib vs. 68% or
69% for idelalisib plus rituximab or BR, respectively. Cross-over to acalabrutinib (23%) was
allowed, and the 12-month OS rates were 94% for patients treated with acalabrutinib vs.
91% for patients treated either with idelalisib plus rituximab or BR. Regarding adverse
events, acalabrutinib showed a favorable safety profile when compared to idelalisib plus
rituximab, with serious adverse events occurring in 29% (acalabrutinib monotherapy),
56% (idelalisib + rituximab), and 26% (BR) of patients. The adverse events profile was as
expected, and treatment discontinuation (11%) or dose reductions (3%) of acalabrutinib
were rare.
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6. PI3K Inhibitors
In 2014, with the approval of the phosphoinositide 3-kinase delta (PI3Kδ) inhibitor
idelalisib by the FDA and EMA for patients with r/r CLL, an additional compound became
available to physicians for a targeted CLL treatment approach. In relapsed CLL patients
with decreased renal function, previous therapy-induced myelosuppression, or major
coexisting illnesses, idelalisib, in combination with rituximab, significantly improved ORR,
PFS, and OS, as compared to rituximab alone [21]. These findings were also seen in the
prespecified subgroups of high-risk patients with del(17p), TP53 mutation, or unmutated
IGHV status. When used as first-line therapy in CLL patients, idelalisib lead to severe
immune-mediated hepatotoxicity, especially in younger patients with mutated IGHV
status. Lymphocytic infiltration of the liver, reduced regulatory T cells, and increased
levels of the proinflammatory cytokines CCL-3 and CCL-4 were reported for patients
experiencing hepatotoxicity (elevation of transaminases). These findings indicate immune-
related mechanisms in the pathogenesis of idelalisib-induced hepatotoxicity [85]. Moreover,
many patients developed gastrointestinal symptoms during idelalisib therapy, which is
probably the most clinically significant side effect of idelalisib. Weidner et al. assumed
that intraepithelial lymphocytosis, epithelial cell apoptosis, and neutrophilic cryptitis are
effects of idelalisib leading to gastrointestinal injury [86,87]. In line with this, in vitro
studies suggest that PI3Kδ inhibition decreases the activity of regulatory T cells (Tregs),
thus stimulating an anti-tumor immune response [88]. Simultaneously to the publication
of the study of Lampson et al., Gilead closed seven trials due to toxicity concerns including
predominantly infectious complications such as pneumocystis jirovecii pneumonia (PJP)
and cytomegalovirus (CMV) reactivation [85]. Therefore, it is now recommended to
administer PJP prophylaxis with co-trimoxazole and to monitor for CMV reactivation
under treatment with idelalisib [3,4]. Despite these concerns, idelalisib remains an effective
treatment option for a small proportion of patients with r/r CLL.
In 2018, the FDA approved the second PI3K inhibitor, duvelisib. It was first developed
as IPI-145 and inhibits both the γ- and δ-isoforms of PI3K. In in vitro studies, duvelisib
led to the apoptosis of CLL cells using sub-nanomolar concentrations. Inhibition of the
δ-isoform of PI3K blocks the survival and proliferation of CLL cells [89–91], whereas
inhibition of the γ-isoform modulates the microenvironment of malignant cells [92–97].
The enhanced activity of duvelisib is thought to be related to the dual inhibition of the
PI3K γ- and δ-isoforms [98]. A first phase 1 trial demonstrated a tolerable safety profile
and clinical activity for duvelisib in advanced hematologic malignancies [99]. Regarding
r/r and tn CLL patients, duvelisib showed an ORR of 56% and 83%, respectively [99].
Compared to idelalisib, the toxicities of duvelisib were similar in this trial, with observed
effects of neutropenia (20% grade ≥ 3), hepatotoxicity (19.5% transaminitis grade ≥ 3),
late-onset diarrhea/colitis (11%/6% grade ≥ 3), infections (10% grade ≥ 3), including three
patients with pneumocystis jirovecii pneumonia and two systemic CMV infections, and
interstitial pneumonitis (4%) [99].
The FDA approval of duvelisib was based on the publication of the pivotal phase 3
DUO trial [23]. In this trial, 319 patients with r/r CLL were randomly assigned to receive
either duvelisib or ofatumumab. Serious adverse events were of special interest in this
trial. Adverse events ≥ grade 3 occurred more often in the duvelisib arm than in patients
treated with ofatumumab (87% vs. 48%) including diarrhea, neutropenia, pyrexia, nausea,
and anemia. PFS and ORR were significantly improved with duvelisib as compared to
ofatumumab (PFS: median, 13.3 vs. 9.9 months; ORR: 74% vs. 45%).
As with idelalisib, the treatment benefit of duvelisib included patients with del(17p)
and TP53 mutation. Nevertheless, at present, it has only been approved in the United States
by the FDA, and due to the abovementioned side effects, it should be used with caution.
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7. Investigational Approaches and Perspectives
Zanubrutinib
Zanubrutinib inhibits BTK irreversibly with similar affinity as ibrutinib, but shows
significantly decreased affinity to other kinases that contain a cysteine at the ATP-binding
site [100,101]. The relatively high affinity of ibrutinib to other kinases seems to be re-
sponsible for its off-target effects that include bleeding, atrial fibrillation, rash, and diar-
rhea [102–104]. Zanubrutinib is much more specific for BTK; therefore, it is thought to be
associated with fewer toxicities. Since November 2019, zanubrutinib has been approved by
the FDA for the treatment of mantle cell lymphoma after at least one line of therapy, and in
February 2021, the FDA accepted the supplemental new drug application for the treatment
of patients with Waldenstrom’s macroglobulinemia [105,106].
The initial phase 1 trial investigating the safety and efficacy of zanubrutinib in CLL
patients included 94 patients with CLL/SLL, 22 of whom were treatment-naïve [101].
Common side effects of any grade were contusion (35.1%), upper respiratory tract infection
(33%), cough (25.5%), and diarrhea (21.3%). Neutropenia occurred in 6.4% as the most
frequent grade 3/4 AE. At a median follow-up of 13.7 months, an ORR of 96.2% (95% CI,
89.2–99.2) and an estimated PFS at 12 months of 100% were reported. A phase 2, single-
arm, multicenter study evaluating zanubrutinib in 91 patients with r/r CLL/SLL yielded
similar results, with an ORR of 84.6% after a median follow-up of 15.1 months and an OS
of 96% at 12 months [107]. The most common grade ≥3 adverse events were cytopenia
and upper respiratory tract infections, which is in line with previous findings. Patients
included showed high-risk characteristics, because 45% of patients had ≥2 lines of previous
therapies, 24% had del(17p) or TP53 mutation, and 56% presented with unmutated IGHV
status. In this trial, zanubrutinib seemed to be very effective in high-risk patients. Tam et al.
recently reported results from a non-randomized cohort (Cohort C) of the phase 3 Sequoia
trial (NCT03336333) including 109 treatment-naïve CLL patients with del(17p) who were
treated with zanubrutinib monotherapy. The ORR was 94.5% and the estimated 18-month
PFS rate was 88.6%. The most common adverse events were respiratory infections and
neutropenia. Atrial fibrillation and major bleedings occurred in three and six patients,
respectively [108]. When combined with the CD20-antibody obinutuzumab, adverse
events seem to occur more often but do not change in their nature; upper respiratory tract
infections (51%) and neutropenia (44%) were still the most common [109]. Combination
therapy of zanubrutinib and obinutuzumab resulted in an ORR of 100% for tn CLL patients
and 92% for r/r CLL patients at a median follow-up of 29 months. A phase 2 trial tested the
safety and efficacy of adding venetoclax to this combination in 39 patients with tn CLL [110].
The endpoints assessed were uMRD in peripheral blood (PB) and bone marrow (BM). The
combination of obinutuzumab, venetoclax, and zanubrutinib was well tolerated, with no
new safety concerns, and achieved uMRD in 68% and 51% in PB and BM, respectively.
8. LOXO-305
Despite the success of BTKis, acquired and primary resistance to conventional (cova-
lent) BTKis can confer clinical resistance [111]. LOXO-305 (Loxo Oncology, Stamford, CT,
USA) is a selective, reversible, non-covalent BTKi which showed potent BTK inhibition
regardless of the presence of a C481S mutation in preclinical models [112]. Recently, results
from an early phase 1/2 trial investigating oral LOXO-305 in patients with r/r CLL/SLL
and non-Hodgkin lymphoma were published by Mato and colleagues.
They enrolled 323 patients in a first-in-human, multicenter, open-label, phase 1/2 trial
to evaluate the safety and efficacy of oral pirtobrutinib (working name; formerly known as
LOXO-305) in previously treated patients with B cell malignancies [113].
In this trial, patients were treated with pirtobrutinib across seven dose levels (25 mg,
50 mg, 100 mg, 150 mg, 200 mg, 250 mg, and 300 mg once per day). They observed no dose-
limiting toxicities, leading to the phase 2 dose of 200 mg daily. Regarding safety profile,
the most often seen adverse events were fatigue (20%), diarrhea (17%), and contusion
(13%). Interestingly, grade 3 atrial fibrillation or flutter were not observed. Five (1%)
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patients discontinued treatment due to a treatment-related adverse event. All patients
with r/r CLL or SLL were treated previously with a covalent BTKi with a median of four
preceding lines of treatment. The ORR in CLL patients was 62% and did not differ between
CLL patients with resistance to covalent BTKi resistance (67%) and patients with BTKi
intolerance (52%) [113]. In summary, these early data show that pirtobrutinib is safe and
active in patients with r/r CLL, including patients previously treated with covalent BTKis.
However, the role of new, non-covalent BTK inhibitors in the treatment landscape of CLL
will have to be clarified in upcoming trials.
9. Combination of BTKi and BCL2i
Ongoing trials are currently investigating the combination of BTKi with BCL2i, based
on the idea of clinically complimentary activity due to the fact that BTKis are highly
active in treating and shrinking nodal disease, while BCL2i is highly effective at clearing
bone marrow and peripheral blood of CLL. Early stage trials showed promising results
in both first-line [114] and relapsed/refractory [115] treatment settings. In these two
trials, the treatment combination of BTKi (ibrutinib) and BCL2i (venetoclax) resulted in
a high uMRD rate (36% in r/r CLL patients [115] and 61% in untreated high-risk and
older patients with CLL [114]). However, it is still not clear what role CD20 monoclonal
antibodies can play in this combination. An answer to that might be given in the recruiting
ACE-CL-311 trial (NCT03836261), which will investigate the combination of venetoclax
plus acalabrutinib with or without obinutuzumab compared to chemoimmunotherapy in
patients with previously untreated CLL.
10. CAR-T Cell Therapy
In recent years, a new treatment option arose for CD19+ B cell malignancies: chimeric
antigen receptor-engineered (CAR)-T cell immunotherapy [116]. Multiple clinical trials
of CD19 directed CAR-T cell therapy have shown efficacy [117–119], which led to the
approval of this therapy by the EMA and FDA for specific indications [118,120,121]. For
the treatment of CLL, CAR-T cells are currently not FDA/EMA-approved. However,
CAR-T cell therapy is available in clinical trials (NCT03331198; NCT03624036) and might
be a very promising treatment option in r/r CLL, offering durable remissions with a
manageable toxicity profile. In a pivotal trial, Porter et al. reported an ORR of 57% in
a heavily pretreated CLL patient cohort (median of five previous therapies) with four
complete remissions (4/14) and four partial remissions (4/14), underlining the strength of
this therapeutic approach [122]. Moreover, uMRD was reached in patients who achieved
CR, which led the authors to the suggestion that disease eradication with CAR-T cells is
possible even in advanced CLL. Moving on, another phase 1/2 open-label clinical trial by
Turtle and colleagues demonstrated that CD19 CAR-T cells are highly effective even in
high-risk patients after BTKi treatment failure [123]. In this trial, the ORR was 74%, with
a CR rate of 21% (4/19) and PR rate of 53% (10/19). Regarding uMRD, no disease was
detectable by flow cytometry after CAR-T cell infusion in 88% of patients with marrow
disease before CAR-T cell treatment. In 12 patients, deep IGH sequencing was performed.
In seven patients (58%), CLL IGH sequences were not detectable after therapy in the
bone marrow, resulting in a 100% PFS and OS (median follow-up 6.6 months) of these
patients [123]. More recently, the open-label phase 1/2 trial TRANSCEND-CLL-004 was
updated. In detail, results of 23 patients (22 were evaluable for efficacy) showed an ORR
of 82% and a CR rate of 45% after a median follow-up of 9 months. In this trial, most
patients (83%) were defined as high-risk, with a median of five prior therapies including
BTKi therapy [124]. However, 60% of evaluable patients had uMRD in the bone marrow
by day 30. Cytokine release syndrome (CRS) was reported in 74% (9% were grade 3–4)
and neurotoxicity in 39% (22% were grade 3–4) of the patients, respectively. Due to more
experience over recent years (e.g., using tocilizumab or corticosteroids), CAR-T cell-related
toxic side effects became more manageable in daily clinical practice. Therefore, with the
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possible exception of allogeneic stem cell transplantation, these remarkable results might
break the paradigm that CLL is not a curable disease.
11. Suggested Treatment Algorithm Upfront and at Relapse
Due to the tremendous changes over the last few years in the treatment landscape for
CLL, the choice of treatment should be based on patient parameters and disease factors.
Patient-related factors should include comorbidities (e.g., based on the Cumulative Illness
Rating Score [125], go–go / fit vs. slow go/frail), organ function, and drug interaction. The
disease factors are known genetic biomarkers/risk factors such as del(17p)/TP53 mutation,
IGVH mutation status, and karyotype. In addition, patients should be enrolled in clinical
trials whenever possible. These factors have to be considered and weighed in the process
of providing individualized therapy for CLL patients.
12. Upfront Treatment
Based on recently published randomized trials comparing CIT regimens with BTKi,
namely, ibrutinib or acalabrutinib, BTKis are now considered a feasible option for all
patients in first-line setting (see Table 1 and Figure 1). Therefore, comorbidities such as
arterial hypertension or renal impairment, need for oral anticoagulation, and patient’s
preference (unlimited therapy with BTKi or fixed treatment duration), should be taken into
account when choosing first-line therapy in CLL patients. Until now, no head-to-head trial
has shown superiority for one or another novel agent (BTKis or venetoclax). Therefore,
venetoclax + obinutuzumab might be the combination of choice if a patient prefers a fixed
treatment duration or if a patient suffers from cardiovascular comorbidities (hypertension
and atrial fibrillation), or if there is a high risk of bleeding. In patients with high tumor
burden and significant risk of tumor lysis syndrome, BTKis might be the treatment of choice,
especially because of easier treatment initiation (no ramp-up needed, oral treatment). They
also may be preferred when quick disease control is needed.
Table 1. Overview of phase 3 trials in tn CLL.
Trial Treatment Arms ORR OS PFS uMRD
ALLIANCE
(A041202) Study [47] Ibr vs. Ibr-R vs. BR
81% (BR) vs. 93%
(Ibr) vs. 94% (Ibr-R)
2-year OS
95% (BR) vs. 90%
(Ibr) vs. 94% (Ibr-R)
2-year PFS 74% (BR)
vs. 87% (Ibr) vs.
88% (Ibr-R)
8% (BR) vs. 1% (Ibr)
vs. 4% (Ibr-R)













5-year PFS 70% (Ibr)
vs. 12% (Clb) N.A.
iLLUMINATE













ELEVATE TN [82] Acb vs. G-Acbvs. G-Clb
94% (G-Acb) vs. 79%
(G-Clb) vs. 85% (Acb)
Estimated
24-month OS
95% (G-Acb) vs. 95%
(Acb) vs. 92% (G-Clb)
Estimated
24-month PFS
93% (G-Acb) vs. 87%
(Acb) vs. 47% (G-Clb)
N.A.













Abbreviations: Ibr, ibrutinib; R, rituximab; F, fludarabine; C, cyclophosphamide; Clb, chlorambucil; G, obinutuzumab; Acb, acalabrutinib;
Ven, venetoclax; N.A., not available.
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Nevertheless, even though novel agents might be the standard of care, CIT (chlorambu-
cil/obinutuzumab, bendamustine/rituximab or FCR) is still an available treatment option
in tn IGHV-mutated CLL patients without del(17p), TP53 mutation, or complex karyotype.
13. Treatment in Relapsed/Refractory Patients
Similar to first-line therapy, r/r CLL should only be treated if symptomatic according
to the International orkshop Group on CLL (iwCLL) criteria [4]. As with tn nCLL patients,
novel therapeutics are superior to CIT regimens, leading to significantly better survival
in r/r CLL patients [4,127]. Both c mbinatio treatment with venetoclax + ritu imab and
BTKis are feasible treatment options n r/r CLL patients (Figure 2 and Table 2).




Figure 1. Frontline treatment algorithm in CLL. 
13. Treatment in Relapsed/Refracto y Patients 
Similar to first-line therapy, r/r CLL should only be treated if symptomatic according 
to the International Workshop Group on CLL (iwCLL) criteria [4]. As with tn nCLL pa-
tients, novel therapeutics are superior to CIT regimens, leading to significantly better sur-
vival in r/r CLL patients [4,127]. Both combination treatment with venetoclax + ri uximab 
and BTKis are feasible treatment options in r/r CLL patients (Figure 2 and Table 2). 
We suggest that re-treatment with venetocl x + rituximab might also be a feasible 
treatment option if patients had a long duration of resp nse without disease progression 
after first-line treatment with venetoclax + obinutuzumab (e.g., after 53.9 months, which 
is the median PFS in the MURANO trial [66]).  
 





















Slow go / frail 









No TP53 mut / 
del(17)p and 
IGHV mutated












Slow go / frail 



















go go / fit
Absence of TP53 























TP53 mut / 






slow go / frail
Figure 2. Treatment algorithm in relapsed/refractory CLL.
Cancers 2021, 13, 2468 12 of 18
Table 2. Overview of phase 3 trials in r/r-CLL.
Trial Treatment Arms ORR OS PFS uMRD





88% (Acb) vs. 68%
(Idl-R) or 69% (BR)
N.A.
MURANO [26,128] Ven-R vs. BR 92% (Ven-R) vs.72% (BR)
4-year OS 85%
(Ven-R) vs. 67% (BR)
4-year PFS 57%
(Ven-R) vs. 5% (BR) N.A.
RESONATE-1
[18,129] Ibr vs. Ofa
86% (Ibr) vs.
24% (Ofa)
3-year OS 74% (Ibr)
vs. 65% (Ofa)
3-year PFS 59% (Ibr)
vs. 3% (Ofa) N.A.
Abbreviations: Acb, acalabrutinib; B, bendamustine; Ibr, ibrutinib; Idl, idelalisib; Ofa, ofatumumab; R, rituximab; Ven, venetoclax; N.A.,
not available.
We suggest that re-treatment with venetoclax + rituximab might also be a feasible
treatment option if patients had a long duration of response without disease progression
after first-line treatment with venetoclax + obinutuzumab (e.g., after 53.9 months, which is
the median PFS in the MURANO trial [66]).
14. Conclusions
Within the last few decades, numerous advances in the treatment of CLL have been
made, including the introduction of novel classes of targeted small molecules such as
BCL2 inhibitors, BTK inhibitors, or PI3K inhibitors. These therapeutics have funda-
mentally changed the treatment of CLL and improved patient outcomes. An improved
progression-free survival with these therapeutics over CIT in both settings, first-line and
relapsed/refractory, was demonstrated in many randomized clinical trials. Of note, these
chemotherapy-free regimens especially helped to improve the outcome in subgroups with
previously very poor prognoses. Unanswered questions, such as whether two- or three-
drug regimens are the best treatment choice or if an endless treatment might be better than
a time-limited treatment, will hopefully be answered in the near future. Ongoing trials
such as the recruiting CLL17 trial (NCT03701282) are addressing this issue.
Nevertheless, despite all these advances, CLL remains an incurable disease, necessi-
tating new clinical trials to improve CLL treatment.
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